OUR
PRODUCTS

About Us

3iPharma Medical Care is dedicated to providing patients with a broad line of formulations containing the main phytocannabinoids. From plantations in San Diego (USA) to patients, 3iPharma follows the production process step by step, bringing the best quality and technology to Brazil in cannabis-derived products.

100% natural products. Produced in the USA on organic plantations, without genetic modification. It has good manufacturing practices (GMP) certification, with raw materials certified by the US Department of Agriculture.

Manufactured by FDA approved facility.

Supercritical CO2 extraction method.

Support with ANVISA, for importing the product.

Product tracking during transportation to Brazil.

• Complete certificate of analysis (COA), including research on cannabinoids, heavy metals, pesticides, terpenes, microtoxins and microbiological research carried out by an independent laboratory;
• Tailor-made COA, per batch of product;
• QR code on the label directed to COA.

Cannabis

The discovery of the endocannabinoid system in the 1980s and 1990s boosted research and publications around the world on the medicinal properties of Cannabis sativa and its interactions with the endocannabinoid system. Brazil was one of the world leaders in research on the phytocannabinoid, cannabidiol, in the 1970s, 1980s and 1990s. Currently, in Brazil, ANVISA's RDC 660/2022 establishes the rules for imports, making it possible to import various derivative products of cannabis, upon medical prescription, in a process that is becoming increasingly less bureaucratic.

The Cannabis Sativa plant has more than 120 described phytocannabinoids, among which the most commonly used for medicinal purposes are:

Cannabigerol (CBG)

Phytocannabinoid known as “father of cannabinoids”. Its acid form CBGA is a precursor to other cannabinoids, via the decarboxylation process. For this reason, CBGA is present in small quantities in plants. CBG has intermediate properties between THC and CBD. Recent research has been exploring its neuroprotective, anti-inflammatory, sedative and antibacterial potential.

Cannabinol (CBN)

CBN was one of the first phytocannabinoids to be isolated, it is one of the only cannabinoids that does not derive from the acid form of CBG. CBN is a degradation product of THC in the plant, especially when exposed to light and heat. Less picotomimetic than THC, CBN has great potential in inducing and maintaining sleep.

Cannabidiol (CBD)

Major, non-psychotomimetic component of Cannabis sativa varieties, first isolated in 1940 and described in 1960. Cannabidiol does not produce dependence or psychotoxicity. It has wide use in oils and medicinal compounds, acting on pain, epilepsy, sleep, as a potential antipsychotic and anxiety reducing agent.

Delta 9 - Tetrahydrocannabinol (THC)

Major psychotomimetic component of Cannabis sativa varieties. It has intoxicating properties if used in large quantities for recreational purposes. THC has interesting therapeutic uses, it plays an important role in controlling pain, sleep, has anti-spasticity effects, anti-nausea and vomiting, loss of appetite, glaucoma and possible benefits in neuroplasticity in the elderly. It should be avoided in the immature brain (children and adolescents), except under well-established conditions.